ARQTArcutis Biotherapeutics, Inc.

ZORYVE franchise revenue surged 59% year-over-year, driving profitability.

Watanabe's sale was non-discretionary, executed to cover tax withholding on vesting RSUs. Watanabe retains 950,000+ shares valued at $24.65 million, signaling continued confidence.

Moby summary of Arcutis Biotherapeutics, Inc.'s Q2 2026 earnings call

Arcutis Biotherapeutics Inc (ARQT) reports strong Q2 2026 results with record revenues, FDA approvals, and a raised full-year outlook.

Arcutis Biotherapeutics (NASDAQ:ARQT) reported second-quarter 2026 net product revenue of $129.9 million, up 59% from the prior-year period and 23% sequentially, as demand for its ZORYVE topical treatments continued to rise across approved dermatology indications. The company generated net income o

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +22.22% and +6.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

VTRS readies Q2 results as growth in key markets and brands may offset manufacturing and pricing headwinds across parts of its portfolio.

OTLK heads into Q3 results with investors watching European Lytenava sales, U.S. launch plans and updates after its landmark FDA approval.

Arcutis Biotherapeutics stock has delivered a very strong 176.6% return over the past three years, yet the broader valuation checks currently suggest it does not stand out as obviously expensive or obviously cheap. With the shares last closing at US$27.99 and the stock screening as "about right" on market multiples, investors are weighing how much of that past return is already reflected in the price. The 176.6% three year return highlights how strongly Arcutis Biotherapeutics has rewarded...

Arcutis Biotherapeutics (ARQT) is back in focus as Wall Street looks ahead to its June 2026 quarter earnings report on August 5, with expectations centered on higher earnings and revenue. See our latest analysis for Arcutis Biotherapeutics. At a recent share price of $27.99, Arcutis Biotherapeutics has seen firm momentum in the near term, with a 30 day share price return of 6.75% and a 90 day gain of 19.87%, set against a year to date share price return that is slightly lower and a very...

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The mean of analysts' price targets for Arcutis Biotherapeutics (ARQT) points to a 25.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.